Evidence map›Paper›PMID 41988375›Full record

ArticleACS pharmacology & translational science2026

Comparing Heparin and Heparin Mimetics in Targeting Immunomodulatory Proteins from Platelets to Activate T Cell-Dependent Immune Response in Oncology.

Katrin Nekipelov, Sven Otto, Maximilian Henseler, Sabine Vidal-Y-Sy, Abdullah Al Nahain, Christian Gorzelanny, Vito Ferro, Gerd Bendas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katrin NekipelovPharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, Bonn 53121, Germany.
Sven OttoPharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, Bonn 53121, Germany.
Maximilian HenselerPharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, Bonn 53121, Germany.
Sabine Vidal-Y-SyDepartment of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.
Abdullah Al NahainSchool of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, QLD 4072, Australia.
Christian GorzelannyDepartment of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.
Vito FerroSchool of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, QLD 4072, Australia.ORCID https://orcid.org/0000-0003-3306-2550
Gerd BendasPharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, Bonn 53121, Germany.ORCID https://orcid.org/0000-0002-8667-7201

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelets play a crucial role in the hematogenous metastasis of cancer. Beyond their mechanical function of forming a protective cloak around circulating tumor cells, which can be antagonized by heparin, activated platelets release various immunomodulatory components. Based on a proteome profiling of releasates, we address the immunosuppressive activities of TGF-β1 and MMP2 to CD4

Indexed as

cancerimmune cellsmetastasisMMP2plateletsTGF-β1

Identifiers

PMID41988375
PMCPMC13077492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.